Andere talen Lobe Sciences Ltd.

Aandelen

Beurs gesloten - Canadian Securities Exchange Andere beurzen 18:50:35 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,02 ^CAD	-20,00%		-20,00%	-20,00%

30/04	Lobe Sciences Ltd. Rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 29 februari 2024	CI
15/02	Lobe Sciences Ltd. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 augustus 2023	CI

Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30/04
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	15/02
Lobe Sciences Provides Company Review of 2023	08/01
Lobe Sciences Provides Update on L-130 Clinical Program	07/12
Lobe Sciences Provides Update on L-130 Clinical Program	07/12
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program	07/12
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	05/12
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	05/12
Lobe Sciences : Corporate Presentation	11-10-23
Lobe Sciences : Corporate Presentation Q3, 2023	09-10-23
Lobe Sciences Appoints CFO	18-09-23
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer	18-09-23
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement	15-09-23
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company	15-09-23
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	01-08-23
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130	27-06-23
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130	27-06-23
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer	07-06-23
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer	07-06-23
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™	17-05-23

Geen resultaten voor deze zoekopdracht